Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Integrilin; Belgium: Integrilin; Bulgaria: Integrilin; Cyprus: Integrilin; Czech Republic: Integrilin; Denmark: Integrilin; Estonia: Integrilin; Finland: Integrilin; France: Integrilin; Germany: Integrilin; Greece: Integrilin; Hungary: Integrilin; Ireland: Integrilin; Italy: Integrilin; Latvia: Integrilin; Lithuania: Integrilin; Netherlands: Integrilin; Poland: Integrilin; Portugal: Integrilin; Romania: Integrilin; Slovakia: Integrilin; Spain: Integrilin; Sweden: Integrilin; UK: Integrilin.

North America

Canada: Integrilin; USA: Integrilin.

Drug combinations


Eptifibatide: C~35~H~49~N~11~O~9~S~2~. Mw: 831.96. N^6^-Amidino-N^2^-(3-mercaptopropionyl)-L-lysylglycyl-L-α-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1-6)-disulfide. CAS-148031-34-9.

Pharmacologic Category

Antithrombotic Agents; Platelet-aggregation Inhibitors; Glycoprotein II~b~/III~a~ Inhibitors. (ATC-Code: B01AC16).

Mechanism of action

Eptifibatide is a cyclic heptapeptide which blocks the platelet GPII~b~/III~a~ receptor, the binding site for fibrinogen, von Willebrand factor, and other ligands. Inhibition of binding at this final common receptor reversibly blocks platelet aggregation and prevents thrombosis.

Therapeutic use

Used to reduce risk of acute cardiac ischemic events (death and/or MI) in unstable angina or non-ST-segment elevation (e.g. non-Q-wave) MI (i.e. non-ST-segment elevation acute coronary syndromes), both in patients who are to receive medical management and those undergoing PCI. Also used to reduce the risk of acute ischemic complications (death, MI, and/or the need for urgent revascularization procedures) in patients undergoing PCI, including coronary artery stenting.

Pregnancy and lactiation implications

Teratogenic effects not observed in animal studies. Use caution.

Unlabeled use


Hypersensitivity to eptifibatide or any component of the product. Abnormal bleeding or history of bleeding diathesis within the previous 30 days. History of CVA within 30 days or history of hemorrhagic stroke. Severe hypertension. Major surgery within the preceding 6 weeks. Current or planned administration of another parenteral GPII~b~/III~a~ inhibitor. Thrombocytopenia. Dependency on renal dialysis.

Warnings and precautions

Bleeding is common (including retroperitoneal, pulmonary, and spontaneous GI and/or GU bleeding). Patients weighing <70 kg may have increased risk of major bleeding. Use with extreme caution in platelet counts <150000/mm^3^, hemorrhagic retinopathy, previous history of GI disease, recent thrombolytic therapy and in chronic dialysis patients. Use caution with administration of other drugs affecting hemostasis. Use not recommended in hematocrit <30%. Use with caution in renal dysfunction (estimated CrCl <50 mL/minute). Use contraindicated in patients undergoing renal dialysis. Concurrent use with thrombolytics not established as safe. Anaphylaxis reported. Thrombocytopenia reported. Use with caution in geriatric patients. Use contraindicated in hepatic disease severe enough to alter synthesis of coagulation factors.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart